Surveillance of Efficacy and Safety of Drug PRITOR in patieNts With Arterial Hypertension, Who do Not Tolerate ACE inhibitoR Treatment

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00932867

Acronym

SONAR

Enrollment

3114

Registered

2009-07-03

Start date

2007-12-31

Completion date

2009-08-31

Last updated

2010-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Keywords

Arterial Hypertension

Brief summary

Surveillance of efficacy and safety of drug PRITOR in patieNts with arterial hypertension, who do not tolerate ACE inhibitoR treatment

Interventions

DRUGKinzal/Pritor (Telmisartan, BAY68-9291)

Patients under daily life treatment receiving Pritor according to local drug information.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients over 18 years of age * Arterial hypertension (SBP \< 160 mmHg and DBP \< 100 mmHg) * Patients, who do not tolerate ACE inhibitors (must be documented in the official ambulant documentation) Inclusion criteria for the control arm (treated by ACEi): * Patients over 18 years of age * Arterial hypertension (SBP \< 160 mmHg and DBP \< 100 mmHg) * Patients, who tolerate ACEi treatment

Exclusion criteria

* Cholestasis, severe hepatic insufficiency * Allergy to telmisartan * Gravidity or lactation

Design outcomes

Primary

Measure	Time frame
To evaluate efficacy and safety of telmisartan in patients with arterial hypertension, who do not tolerate ACEI treatment	1 year

Countries

Romania, Slovakia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026